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a b s t r a c t
Childhood tuberculosis (TB) indicates a recent infection, particularly in children aged< 5 years, and therefore
is considered a sentinel event insofar as it highlights the presence of an undiagnosed or untreated source case.
The risk of acquiring TB is directly proportional to the number of bacilli to which a subject is exposed and
the environment in which the contact occurred. This document contains the recommendations of a group of
Italian scientiﬁc societies for managing a child exposed to a case of TB based on an analysis of the risk factors
for acquiring latent tuberculous infection (LTBI) and developing the disease, and the particular aspects TB
transmission during the ﬁrst years of life. The guidance includes a detailed description of the methods used
to identify the index case, the tests that the exposed child should receive and the possibilities of preventive
chemoprophylaxis depending on the patient’s age and immune status, the chemotherapy and monitoring
methods indicated in the case of LTBI, the management of a child who has come into contact with a case
of multidrug-resistant or extensively drug-resistant TB, and the use of molecular typing in the analysis of
epidemics. The group of experts identiﬁed risk factors for tuberculous infection and disease in pediatric age
as well as gave recommendation on management of contacts of cases of TB according to their age, risk factors
and exposure to multidrug-resistant or extensively drug-resistant TB.
© 2015 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Quality of evidence and strength of recommendation.
Quality of evidence
I Evidence from more than one properly designed, randomised,
controlled study and/or systematic review of randomised studies
II Evidence from one properely designed, randomised, controlled study
III Evidence from cohort studies or their meta-analysis
IV Evidence from retrospective case-controlled studies or their
meta-analysis
V Evidence from case series without control group
VI Evidence from opinions of respected authorities, based on clinical
experience
Strenght of recommendation
A The panel strongly supports a recommendation for use
B The panel moderately supports a recommendation for use
C The panel marginally supports a recommendation for use
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Childhood tuberculosis (TB) indicates a recent infection, par-
ticularly in children aged <5 years, and therefore is considered a
sentinel event insofar as it highlights the presence of an undiagnosed
or untreated source case [1]. The transmission of Mycobacterium
tuberculosis is usually due to the inhalation of airborne particles or
droplets containing 2–3 micro-organisms spread by the sneezing or
coughing of an adolescent or adult with bacilleferous pulmonary or
laryngeal TB.
It is now universally accepted that the risk of acquiring TB is di-
rectly proportional to the number of bacilli to which a subject is ex-
posed [2]. In the ﬁrst place, it depends on the characteristics of the
source case: contagiousness is generally limited to subjects with lung
disease, and is greater among the patients with bacilleferous forms
(i.e. those with positive microscopic test results), in whom the es-
timated transmission rate is about 35% as against the 17% observed
among those with non-bacilleferous forms [3,4]. It is also known that
subjects with cavitating TB and frequent cough are more bacillifer-
ous and contagious than those with other pulmonary pictures or who
cough less frequently [5]. Furthermore, any manoeuvre capable of
stimulating coughing can lead to more aerosolised respiratory secre-
tions and consequently increase contagiousness. The subjects with
extra-pulmonary disease (meningitis or abdominal, renal or bone TB)
are generally considered not to be contagious, but the absence of
pulmonary involvement must be documented before this can be de-
clared [5]. Childrenwith TBwho are less than 10 years old are less fre-
quently contagious because their pulmonary lesions are usually small
and paucibacillary, and their cough is often unproductive [3,6].
The number of bacilli to which a subject is exposed is strictly re-
lated to the environment in which the contact takes place. Enclosed
and poorly ventilated places favour the concentration of tubercular
bacilli in the air and increase the likelihood of transmission, whereas
contacts in the open air or well-ventilated environments decrease
it [7]. Similarly, it is important to evaluate the time spent in an en-
closed space with the source case. The effect of the combination of
these two variables has been clearly shown in studies of the contacts
arising during air ﬂights [8]. Living together gives rise to the great-
est exposure to TB: this has been documented in studies such as that
of Singh et al. who evaluated the prevalence of TB in children living
with adults with active TB and found a signiﬁcant difference between
those living with adults with microscopic positive or negative expec-
torate (respectively 68.4 and 31.6%) [6].
Only few, highly variable and conﬂicting data are available con-
cerning transmission by pediatric source cases, all of which come
from individual case reports: the rate of transmission when a child orItaliana di Infettivologia Pediatrica (SITIP), represented by Susanna Esposito, Maur-
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Pdolescent has microscopic positive expectorate or gastric aspirate
anges from 0.5 to 39.3% [5], whereas the only two reported cases
f children with microscopic negative expectorate/gastric aspirate
ransmitted TB to 29.8 [9] and 72.4% [10] of their contacts. However,
he exiguous number of described cases and the lack of information
oncerning the presence of other risk factors for the acquisition of TB
n the contacts does not allow any conclusions to be drawn concern-
ng the real rate of transmission when the source case is a child.
This document contains the recommendations of a group of Italian
cientiﬁc societies for managing a child exposed to a case of TB based
n an analysis of the risk factors for acquiring latent tuberculous in-
ection (LTBI) and developing the disease, as well as the particular
volution of TB during the ﬁrst years of life.
ethodology
The Consensus Conference method was used, following the
ational Institutes of Health and the National Plan Guidelines as
reviously reported (Table 1) [11,12]. Relevant publications in English
ere identiﬁed through a systematic review of MEDLINE and the
ochrane Database of Systematic Reviews from their inception
hrough December 31, 2014. Search strategy:”children[Title/Abstract]
R pediatric[Title/Abstract]) OR paediatric[Title/Abstract]) AND tu-
erculosis[Title/Abstract]) AND English[lang])”. The Working Group
greed on a list of clinical problems relevant to the management of
hildren at risk of, or exposed to TB. The evidence review procedures
ocused on patients aged 0–18 years and included section-speciﬁc
argeted searches as well as formal systematic reviews on selected
opics. In addition, the clinical recommendations reported in relevant
nd updated international guidelines have been reviewed and criti-
ally compared in case of debated issues. All the data were included
n tables of evidence for each topic. Trained personnel performed
he critical appraisal of the acquired literature using the Scottish
ntercollegiate Guidelines Network methodological checklists [13].
ubsequently, the bibliographical material and a preliminary draft of
he document were provided to the panel members. In the various
eetings, literature evidence was reported and discussed and the
elphi method was used to reach a consensus when the evidence
id not provide consistent and unambiguous recommendations [13].
he ﬁnal text was revised on the basis of these discussions and
ubmitted by e-mail to participants at the Consensus Conference
or ﬁnal approval. The multidisciplinary panel of clinicians and
xperts in evidence-based medicine were identiﬁed with the help
f the participating scientiﬁc societies. Speciﬁcally, the panel in-
luded experts in the ﬁelds of general pediatrics, pediatric infectious
iseases, infectious diseases, pneumology, microbiology, radiology
nd methodologists and was coordinated by the Italian Society of
ediatric Infectious Diseases (SITIP). No panel member declared any
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aonﬂict of interest considering the guideline topics. The panel met on
hree occasions, and many of the consultations involved in the doc-
ment development took place interactively by e-mail or telephone
ontact.
hen should childhood TB be suspected?
Tuberculous infection should be suspected in the presence
f two not mutually exclusive conditions: (1) conditions of so-
ial/familial/epidemiological risk that may have exposed even an
symptomatic child to a high risk of infection; and (2) the presence
f the typical symptoms and signs of the disease even in subjects
onsidered to be at low risk [1]. However, given the re-emergence of
he infection and the potential seriousness of TB for the health of the
atient and that of the general public, the possibility ﬁnding oneself
acing a case of TB must always be considered.
The principal risk factors are described below.
actors related to exposure
In case of contacts with a patient affected by TB (most of whom
re adults), the absence of symptoms is not enough to rule out TB in
hildren and it is always necessary to take the type of contact and
ther risk factors into account [14-16].
A recent meta-analysis [17] has shown that contact with
xpectorate-positive TB patients is a factor indicating a similar risk
f infection in both high-income (odds ratio [OR] 3.3; 95% conﬁdence
nterval [CI] 2.2–4.8) and low-income countries (OR 3.3; 95% CI 2,2–
.1).
The risk of acquiring tuberculous infection is particularly high in
hildren who live with expectorate-positive adults (relative risk [RR]
.78; 95% CI 3.51–13.10) or adults with cavitating lesions revealed by
hest X-ray (RR 2.45; 95% CI 1.60–3.76), or in those who have close
ontacts with drug users (RR 1.81; 95% CI 1.03–3.19) [18,19]. Children
hose families includewomenwith TB are exposed to an even higher
isk (RR 1.34; 95% CI 1.34–3.14), probably because their contacts are
ore frequent than in the case of male relatives [18].
One case-control study carried out in Thailand found that the risk
f developing the diseasewas high in children having any kind of con-
act with TB patients (very close: OR 85.67; 95% CI 33–647.79; p <
.001; close: OR 31.11; 95%CI 4.18–255.94; p = 0.001; not close: OR
2.70; 95% CI 4.18–255.94; p < 0.001) [20].
An increased risk of thoracic TB has been found in children living
ith adults affected by cancer (OR 2.46; 95% CI 1.14-7.37; p = 0.005)
21], which indirectly suggests that the risk of developing TBmay also
e increased in children living with patients with chronic diseases
apable of altering their immune status.
ocio-economic and environmental factors, and factors related to origin
The clinical evaluation of childrenwith suspected tuberculous dis-
ase should be completed by an assessment of the socio-economic
haracteristics of their immediate families because children living in
isadvantaged, precarious or economically insecure conditions are at
reater risk of developing infections – and TB is no exception.
Living arrangements and housing conditions play an important
ole: a case-control study carried out in Bangladesh found that co-
wellers were protected against transmission if there were < 2 peo-
le per bedroom (OR 0.29; 95% CI 1.79–6.03; p < 0.0001), if the
itchen was separated from the bedroom (OR 0.35; 95% CI 0.2–0.62;
= 0,001), and if the home was adequately ventilated (OR 0.25; 95%
I 0.13–0.49; p< 0.0001) [15]. The risk of transmission is also affected
y overcrowding and the economic conditions of the family (OR 1.35;
5% CI 1.06–1.72; p < 0.017) [20,22,23], as well as by an inadequate
upply of food (OR 1.52; 95% CI 1.15–2.02; p < 0.003) [23].In terms of parental socio-cultural status, children whose moth-
rs are illiterate (OR 2.65; 95% CI 1.45–4.86; p = 0.002) [15] or have
nly received primary or lower secondary education (p = 0.01) are at
reater risk of contracting TB [24], whereas living in a family with an
dequate annual income is a protective factor (OR 0.47; 95% CI 0.28–
.77) [14].
The only environmental risk highlighted by many studies is pas-
ive exposure to cigarette smoke, which was found to lead to a more
han 7-fold increase in the risk of childhood TB in a prospective study
arried out in India (OR 7.43; 95% CI 1.12–49.47; p = 0.04) [24]. An-
ther study has shown that the risk of TB is very high in children
n very close contact with smokers (OR 6.42; 95% CI 2.13–19.93; p <
.001), but not in those whose contacts are less close (OR 0.55; 95% CI
.25–1.23; p = 0.146) [20]. Finally, a South African study showed that
atients living with two or more smokers are at increased risk of hav-
ng a TST result of > 5 mm (OR 2.79; 95% CI 1.30–5.97; p = 0.0085),
10 mm (OR 2.66; 95% CI 1.28–5.25; p = 0.0085) or > 15 mm (OR
.94; 95% CI 1.44–6.00; p = 0.003) [20], whereas the consumption of
ruit and vegetables 5–7 times a week seems to be a protective factor
OR 0.38; 95% CI 0.16–0.92; p = 0.03) [20].
Origin and ethnicity should also be carefully investigated when
rawing up the history of patients with suspected TB as migrants
rom areas in which TB is endemic are often infected and therefore
t risk of developing the disease after settling in countries in which
ndemicity is low.
A study carried out in the United States between 1994 and 2007
ecorded incidence rates that were about ten times higher in chil-
ren of foreign origin: the risk was similarly distributed across pedi-
tric age groups, with rate ratios of 12.9 in those aged < 1 year, 10.9
n those aged 1–4 years, 15.4 in those aged 5–12 years, and 18.58 in
hose aged 13–17 years [25]. A similar study carried out in North Car-
lina analysed incidence rates between 1994 and 2002 on the basis
f the patients’ ethnic origin, and found that the incidence of TB was
igher among hispanics (4.5 × 100,000 person/years; p = 0.01) and
on-hispanic blacks (3.0 per 100,000 person/years; p = 0.003) than
mong non-hispanic whites (0.2 per 100,000 person/years) [19].
A Canadian study found that an independent risk factor was com-
ng from south–east Asia (OR 2.41; 95% CI 1.15–5.06), the eastern
editerranean area (OR 2.65; 95% CI 1.23–5.69), central Europe (OR
.00; 95% CI 1.18–7.64), thewestern Paciﬁc area (OR 3.44; 95% CI 1.67–
.08), Latin America (OR 4.03; 95% CI 1.93–8.39) or African countries
ith a high (OR 3.90; 95% CI 1.57–9.73) or low prevalence of HIV (OR
.00; 95% CI 1.33–6.78) [26].
Although the published data do not distinguish patients on the
asis of age, some ethnic groups are not only at greater risk of con-
racting TB, but are also more likely to develop extra-pulmonary and
iliary TB [27], as well as drug-resistant forms [28]. It is therefore
ossible to outline a socio-economic and cultural proﬁle of the chil-
ren at considerably higher risk of developing TB and experiencing
orse outcomes: those living in hygienically and economically in-
dequate conditions characterised by overcrowding and close con-
acts with multiple adults, and often belonging to families of no ﬁxed
bode.
hat are the risk factors for the development of childhood TB?
Only about 5–10% of subjects with primary M. tuberculosis infec-
ion develop active disease [29]; in the other 90–95%, the infection
which remains latent) is contained by the immune system, and so
hey are asymptomatic and non-contagious [29]. Once contagion has
ccurred, the risk of progression to tuberculous disease is highest
uring the ﬁrst six weeks, declines exponentially over the next seven
ears, and then remains more or less constant for the rest of life [5].
he risk of progression also depends on age: the risk of developing
ctive disease is signiﬁcantly higher in children than in adults, being
bout 15% in adolescents, 24% in children aged 1–5 years, and 40–50%
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Table 2
Groups of children and adolescents at greater risk of developing active TB.
• Children (particularly those aged < 5 years)
• Patients with HIV infection, or another congenital or acquired
immunodeﬁciency
• Subjects with selective genetic defects affecting the signalling pathways
mediated by IL-12 and IFN-ʏ
• Patients with diabetes mellitus
• Patients undergoing prolonged corticosteroid therapy (>4 weeks)
• Patients receiving other immunosuppressive treatments with anti-blastic or
anti-rejection agents, or TNF-α antagonists
• Patients with haematological diseases or diseases of the reticulo-endothelial
system
• Patients with severe chronic renal insuﬃciency
• Patients with chronic malabsorption syndrome
• Smokers
• Subjects with a low body weight and/or malnutrition
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tin those aged < 2 years [5]. Furthermore, the tendency to evolve into
active disease is more frequent in children and its clinical course is
more rapid, and (particularly if they are aged < 2 years) children are
at greater risk of developing themore severe forms such as tubercular
meningitis or miliary TB [29].
It has been found that the risk of progression to active disease
is increased in immunocompromised subjects, particularly those
with impaired cell-mediated immunity, such as those with HIV
infection or congenital T cell immunodeﬁciency, and those treated
with immunosuppressants or chemotherapeutic drugs (Table 2).
In particular, HIV-infected subjects and those whose immunity is
severely impaired have a 20–40 times greater risk of developing TB
than the general population [30], and it is clear that the risk of clinical
progression is even higher in immunocompromised children and
children who also have concomitant conditions such as malnutrition
or diabetes [30].
Finally, the ﬁndings of epidemiological and genetic studies sug-
gest that there are genetically determined conditions that make cer-
tain individuals susceptible to tuberculous disease. It is thought that
some carriers of mutations in the genes encoding interleukin(IL)-12
beta and beta-1 receptors or interferon(IFN)-γ receptors 1 and 2 (im-
portant receptors in the IL-12/IL-23/IFN-γ axis) are more susceptible
not only to TB, but also to non-tuberculous mycobacteriosis, which is
usually not pathogenic in immunocompetent subjects [31-33].
How should a child who has come into contact with a case of TB
be managed?
Numerous studies have highlighted the fact that investigating the
contacts of patients is a valuable means of identifying new cases of
TB [5]. In less endemic countries such as Italy, the disease is mainly
controlled by preventing the transmission of M. tuberculosis, which
involves isolating contagious subjects, starting treatment as early as
possible, and preventing the progression of LTI to active TB. Reporting
new cases to the public health authorities is essential in order to trace
people who have been in contact with them.
Contact tracing makes use of a method based on concentric cir-
cles in which priority is established by considering the duration of
exposure to the index case during the period of contagiousness and
the environmental conditions in which it occurred [5]. The search
ﬁrst considers close contacts and those known to be at risk and, if
the prevalence of infection among these is higher than in the general
population or the index case is highly contagious, should be extended
to include regular and ﬁnally occasional contacts.
If a case of TB occurs in a school, the people responsible for
surveillance should visit the school in order to evaluate its structural
characteristics and logistical situation, and obtain a schedule of the
curricular and extra-curricular activities of the teachers, ancillary
staff and pupils [5]. If a pupil is diagnosed as having respiratory TB,riority should be given to evaluating all of the other attending the
ame teaching classes; if the same diagnosis is made in a teacher,
riority should be given to evaluating the pupils who have attended
he teacher’s lessons during the previous three months. The need
o include the pupils, teachers and ancillary staff of other classes
hould be decided on the basis of: (1) the results of the screening
f the high-priority subjects described above; (2) the degree of
ontagiousness of the index case; (3) the length of time spent with
he index case; (4) the contacts’ susceptibility to infection; and (5)
loseness of the contact.
If the index case is aged ≤5 years and the source of contagion
as not been identiﬁed among family members, it should be sought
mong all of the personnel of the child’s day/play school environ-
ent; if the index case is more than ﬁve years old, consideration
hould be given to the need to seek the source at the child’s school
f there is evidence supporting this possibility or if there is nothing to
uggest the presence of the source elsewhere [5].
Hospitalised patients or institutional resident who are acciden-
ally exposed to a case of respiratory TB should be concentrically
creened with priority being given to those who have spent at least
ight hours in an enclosed space with the index case and those at
ncreased risk of disease progression [5].
The main aims of screening children who have come into contact
ith a case of TB are: (1) to identify those who are symptomatic (i.e.
hildren of any age with undiagnosed tuberculous disease; and (2) to
ive prophylaxis to susceptible subjects (i.e. asymptomatic children
ged ≤5 years who have been in close contact with a microscopic
ositive case of pulmonary TB but who do not have active disease,
nd immunocompromised children).
The best methods of screening contacts for TB are tuberculin skin
esting (TST), an IFN-γ release assay (IGRA) and chest radiography
1,31].
Children aged ≤5 years and severely immunocompromised sub-
ects who have been screened as indicated above should undergo a
omplete clinical examination including a chest X-ray even in the
ase of negative TST and IGRA results [5]. An IGRA is recommended
or subjects who have been vaccinated with BCG in order to con-
rm/exclude the presence of TB in subjects with a positive TST; it is
lso recommended for the same reason in HIV-infected subjects. Its
se as an alternative to a TST is not supported by the currently avail-
ble evidence.
In the case of contact screening, a TST is considered positive when
t reveals an induration with a diameter of ≥5 48–72 h after inocula-
ion (or a diameter of > 10 mm if the child has been BCG vaccinated)
1,34,35]. All contacts who are TST and/or IGRA positive should un-
ergo chest radiography.
TST-positive contacts should undergo chest radiography and be
linically monitored.
Children with positive TST and/or IGRA results and a chest X-ray
ompatible with TB should undergo microbiological investigations.
Children with positive TST and/or IGRA results and a normal
hest X-ray are considered infected and should therefore be treated
or LTBI.
In the management of children aged ≤5 years who have been ex-
osed to a case of respiratory TB, the purpose of the TST or IGRA
nd chest X-ray is to exclude tuberculous disease [5]. If the initial
est (TST or IGRA) and the chest X-ray are both negative, primary
hemoprophylaxis should be started with isoniazid 10 mg/kg/day
or 8–12 weeks (the incubation period), after which the TST or
GRA should be repeated and, if still negative, the chemoprophylaxis
hould be stopped.
However, if it becomes positive, if the child is asypmptomatic and
f the chest X-ray is negative, the child should be considered as hav-
ng LTBI, and the chemoprophlylaxis should be continued for a total
f 6–9 months (if the child is immunocompetent) or 12 months (if
he child is immunocompromised) [34,35]. On the other hand, if the
L. Lancella et al. / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 1 (2015) 1–12 5
Fig. 1. Management of children aged ≤5 years exposed to a case of TB and exposed immunocompromised children of any age.
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dST/IGRA becomes positive, and the child is symptomatic and/or the
hest X-ray is abnormal, the diagnosis of TB is likely [36].
If the contact is an HIV-infected child, isoniazid prophylaxis
hould be considered regardless of age [34,35].
Fig. 1 summarises the management of children aged ≤5 years
xposed to a case of TB and the management of exposed immuno-
ompromised children of any age.
Children aged >5 years who have been exposed to a case of con-
agious TB must also be investigated in order to exclude tuberculous
nfection [5]. If the TST or IGRA and chest X-ray are negative, it is not
ecessary to start primary chemoprophylaxis unless the child is im-
unocompromised (in which case, isoniazid should be administered
or 8–12 weeks) [5], and all of the children should undergo a repeat
ST or IGRA 8–12 weeks after the ﬁrst. The children with a positive
nitial TST or IGRA should undergo chest radiography and, if the X-ray
s negative and the child is asymptomatic, the diagnosis is LTBI and
reventive isoniazide chemotherapy should be started; if the test is
egative, no treatment is necessary. If the TST or IGRA is positive,
he patient is symptomatic and/or the chest X-ray is pathological,
he diagnosis is tuberculous disease and speciﬁc treatment should be
tarted.
Fig. 2 summarises the management of children aged > 5 years ex-
osed to a case of TB.
An exposed asymptomatic child does not have to be kept away
rom school or prevented from playing with other children [5]. As
tated above, unlike adults, children with TB are rare contagious for
arious reasons: ﬁrst of all, they often have paucibacillar disease that
eads to a low index of positivity for resistant acid-fast bacilli (AFB)
n respiratory samples [37]; secondly, they less frequently have cavi-
ating pulmonary forms partially because of their immature immune
esponse [38]; thirdly, the cough of prepubertal children is less vi-
lent and less productive that of adults, and aerolization is reduced
39]; fourthly, pediatric TB is more frequently extra-pulmonary than
he TB encountered in immunocompetent adults [1,40–42].
However, there are various reports of TST conversion in health-
are personnel exposed to breastfeeding infants with congenital
iliary TB [38,39]. These children had a high bacilliferous load and,urthermore, the TB was initially unsuspected, which led to delays
n its diagnosis and the isolation of the patient. As a general rule,
ll children with speciﬁc symptoms and radiographic characteristics
f pulmonary TB similar to those observed in adults should be
onsidered potentially contagious.
ow is childhood latent tuberculous infection (LTBI) deﬁned, and
ow should it be treated and monitored?
LTBI is deﬁned as the condition created when M. tuberculosis has
ntered the body and stimulated an immune response [1]. The only
ign of LTBI is a positive TST or IGRA. A child with LTBI has a positive
ST and/or IGRA, no clinical sign of disease, and a chest X-ray that
ay be normal or reveal the presence of a remote infection such as
odular parenchmal calciﬁcations or calciﬁed intra-thoracic lymph
odes. People with LTI are not contagious [1].
It has been estimated that about one-third of the world’s popula-
ion are carriers of latentM. tuberculosis [1]. Immunocompetent sub-
ects with LTBI have a 10% lifetime risk of developing TB, and half of
hese will develop the disease within 2–5 years of being infected, but
he risk is signiﬁcantly greater in immunocompromised subjects, be-
ng 5–10% per year of life in those co-infected with HIV [1].
The rationale underlying the treatment of LTBI is based on the
ossibility of eliminating dormant bacilli, thus reducing their activa-
ion and the development of active disease. Preventive chemotherapy
nvolves the administration of isoniazid at a dose of 10 mg/kg/day
maximum dose: 300 mg/day) for at least six months [1] but, as
ome studies have shown that the treatment is less eﬃcacious if
dministered for less than nine months, many countries recommend
reatment for at least this length of time [36]. A Cochrane review
as shown that treating LTBI with isoniazid reduces the risk of pul-
onary and extra-pulmonary TB and the related deaths, but there
oes not seem to be any signiﬁcant difference in the eﬃcacy of 6- and
-month treatment [43]. Some European countries have proposed
hort-term chemoprophylaxis with isoniazid (10 mg/kg/day, max-
mum dose 300 mg/day) and rifampicin (10 mg/kg/day, maximum
ose 600mg/day) for 3–4months, which has led to promising results
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Fig. 2. Management of children aged > 5 years exposed to a case of TB.
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min both children and adults [44]. Its eﬃcacy seems to be equivalent
to that of isoniazid monotherapy, but compliance is improved.
Routine laboratory monitoring is not recommended for children
receiving isoniazid alone [5], but laboratory tests should be car-
ried out if signs or symptoms of possible adverse events appear.
In the case of hypertransaminasemia, no action is necessary unless
transaminase levels are more than ﬁve times above the upper normal
limit; however, if they are above this level, treatment should be dis-
continued [35]. Isoniazid chemoprophylaxis should be resumed once
the results of liver function tests have normalised and the symptoms
of toxicity have disappeared. The administration of pyridoxine (vita-
min B6) 10–25 mg/day is recommended in the case of breastfeeding
infants, and children with diabetes, HIV infection, malnutrition or pe-
ripheral neuropathy [36].
How should a child who has come into contact with a case of
multidrug-resistant (MDR-TB) or extensively drug-resistant TB
(XDR-TB) be managed and treated?
As only a few studies have analysed the usefulness of prophylaxis
in the contacts of patients with MDR-TB (particularly in the pediatric
population), there is insuﬃcient evidence concerning the eﬃcacy of
the different post-exposure management and prophylactic strategies
[35]. Close contacts such as family members are at greater risk of in-
fection because of the frequency or duration of their contacts, which
may have lasted weeks or even months before the index case has
been diagnosed treatment has been started [5]. In their recent ret-
rospective study cohort of 1,299 children in the families of patients
with TB-MDR in Peru, Becerra et al. analysed the risk of developing
TB and concluded that the risk was more than 30 times higher than
in the general population [45]. The screening of relatives and other
close contacts is therefore highly recommended in order to diagnose
new cases early and prevent further transmission [46].
The available literature is concordant concerning the risk evalua-
tion of children who have come into contact with MDR-TB patients
[34,35,47-52]. Once the presence of active disease has been excluded,
the probability of infection should be assessed by combining TST and
IGRA results, and determining the duration and type of exposure tohe index case and primary chemoprophyaxis can be started only in
igh-risk categories of MDR-exposed children.
Seven observational studies involving a total of more than 200
hildren have investigated the usefulness of primary chemoprophy-
axis [53-58]. Kritski et al. retrospectively analysed 134 adults and
4 children aged 0–15 years who had come into contact with cases
f MDR-TB in Rio de Janeiro, and found that the 45 contacts who
ad received prophylactic treatment with isoniazid 400 mg/day for
ix months were not signiﬁcantly more protected [53]. Active disease
as more frequently observed inmale contacts (p< 0.05), those aged
15 years (p < 0.001), and those who had not been previously vacci-
ated with BCG (p < 0.05). It is worth noting that the contacts who
eveloped the disease despite isoniazid prophylaxis were infected by
. tuberculosis strains resistant to isoniazid and rifampicin, and had
ad the same picture of resistance as their index case [54]. In the
etting, Sneag et al. retrospectively showed that primary prophylaxis
ith isoniazid or a combination of isoniazid, rifampicin and pyrazi-
amide did not prevent the development of the disease in ﬁve child
ontacts [54]. According to the authors, it may worth considering 6–
2 months chemoprophylaxis with at least two second-line drugs to
hich the isolate of the index case has proved to be sensitive.
A South African study of 105 child contacts of cases of MDR-
B found a signiﬁcant difference between observation alone and
he administration of multi-drug chemoprophylaxis based on the
ensitivity of the strain isolated in the index case: only 5% of the
reated children developed active disease as against 20% in the
ontrol group [55]. The prophylactic strategies included isoniazid
15–20 mg/kg/day), pyrazinamide (25–35 mg/kg/day), ethionamide
10–15 mg/kg/day) and/or ethambutol (15–20 mg/kg/day) and/or
ﬂoxacin (15 mg/kg/day).
In their recently published cohort study, Seddon et al. demon-
trated the good tolerability and eﬃcacy of combined chemopro-
hylaxis with high-dose oﬂoxacin, ethambutol and isoniazid for six
onths in 186 children aged < 5 years or with HIV infection who had
een exposed to MDR-TB [56].
Pineiro Perez et al. prospectively followed up nine children who
ad come into contact with the same case of MDR-TB every three
onths for two years, during which no case of TB was observed
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Table 3
International guidelines for managing children who have come into contact with a case of MDR-TB.
Guidelines Primary chemo- prophylaxis
recommended?
Type of chemo-prophylaxis
(if recommended)
Comments
Joint statement of the US Centers for
Disease Control and Prevention,
the American Thoracic Society,
and the Infectious Diseases
Society of America, 1992 [47]
Yes Chemoprophylaxis including two drugs to
which the strain of the index case is
sensitive
Partners in Health, 2003 [48] No The routine use of primary chemo-prophylaxis is not
recommended because of the lack of data.
However, the child should be closely monitored
and, in the case of clinical worsening, treatment
should be started bearing in mind the sensitivity
proﬁle of the strain isolated in the index case.
WHO, 2014 [34] No After being screened in order to exclude active
disease, the child should undergo regular clinical
monitoring for at least at least two years and
closely observed for the onset of active disease
American Academy of Pediatrics,
2009 [35]
Yes Combined primary chemoprophylaxis is
recommended, with preference given to
pyrazinamide, ethambutol and
ﬂuoroquinolones
NICE, 2011 [49] No Clinical follow-up is recommended
Department of Health, Republic of
South Africa, 2011 [50]
Yes, for children aged < 5
years
Chemoprophlaxis with high doses of
isoniazid (15 mg/kg) is suggested for
children aged < 5 years
Al-Dabbagh M et al., 2011 [51] Yes Chemoprophylaxis for 9–12 months using at
least two drugs (preferably pyrazinamide
and a ﬂuoroquinolone); the choice should
be guided by the sensitivity of the strain
isolated in the index case.
A strict follow-up is recommended in all cases.
Prophylaxis should be started immediately in
children aged < 4 years whereas, in those aged ≥4
years, it may be reasonable to wait until the TST
has been repeated 8–12 weeks after the time of
contact.
Seddon JA et al., 2012 [52] No A rigorous follow-up is recommended in order to
identify the possible onset of disease early.
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a57]. They therefore suggested that an optimal management strategy
as close patient monitoring with a clinical evaluation every three
onths and a chest X-ray every sixmonths.Watchful waiting has also
een advised by Fred et al., who recommended close monitoring over
ime as the preferential approach [58].
A retrospective analysis of 10 children prophylactically treated
ith different regimens after coming into contact with patients with
DR-TB between 2004 and 2008 found that the only child with LTBI
eveloped active disease because of inadequate treatment on the ba-
is of the resistance proﬁle of the isolate of the index case [59]. The
uthors suggested that contacts should be monitored and only be
iven LTBI prophylaxis based on the drug-resistance proﬁle of the
train isolated in the index case.
In brief, although the ﬁndings of these studies do not allow any
eﬁnite conclusions to be drawn, the results suggest that chemopro-
hylaxis can be advantageous in children exposed to MDR-TB, partic-
lar those at greater risk of developing active disease [52].
There are some considerable differences among the international
uidelines concerning the management of children exposed to MDR-
B (Table 3). Four of the eight guidelines do not recommend the
outine use of chemoprophylaxis on the grounds that the avail-
ble data are insuﬃcient [34,48,49] and, although the remaining
our do recommend prophylaxis, they suggest different approaches
35,47,50-52]. The South African guidelines recommend treating all
symptomatic child contacts aged < 5 years with high-dose iso-
iazid (15 mg/kg) [50]. The USA suggest individualised multi-drug
egimens based on the sensitivity of the strain isolated in the in-
ex case, with pyrazinamide, ethambutol or a ﬂuoroquinolone be-
ng considered pharmacological options [35]. A joint declaration by
he US Center for Disease Control and Prevention, the American Tho-
acic Society and the Infectious Diseases Society of North America,
s well as the Canadian guidelines recommend that high-risk con-
acts should promptly receive primary chemoprophylaxis with two
nti-tubercular drugs to which the strain isolated in the index cases sensitive [47,51], with preference being given to pyrazinamide and
ﬂuoroquinolone. However, all of the guidelines agree that children
xposed to a case of MDR-TB should be rigorously followed up.
Among the authors of the main reviews of the subject, Seddon
t al. advise the use of chemoprophylaxis with isoniazid and a ﬂu-
roquinolone for at least six months in selected cases (e.g. children
nfected with HIV and/or those aged <5 years [52], whereas others
uggest watchful waiting [60-62].
Table 4 lists the drugs used for post-exposure chemoprophylaxis,
lthough there is limited data concerning their tolerability and ad-
erse events, or their eﬃcacy in children with MDR-TB [63]. Ette-
ad et al. have recently published a meta-analysis of eight studies
nvolving a total of 315 children describing therapeutic outcomes
64]. Adverse events at the time of the use of anti-tuberculosis drugs
ere reported in 39.1% of cases: the most frequent was nausea, but
he others included hearing loss (9–10%, with amikacin or capre-
mycin), psychic disorders (10.5-12.5%, with cycloserine), hypothy-
oidism (7.9–9.1%, with ethionamide), reduced visual acuity (9.1–
2,5%, with ethambutol), increased creatinine kinase/muscle pain
9.1–12,5%, with amikacin or capreomycin) and tendinitis (12.5%,
ith levoﬂoxacin).
Using a ﬁrst-line, oral anti-TB drug to treat the contacts of a pa-
ient with MDR-TB may be questioned because of the possible re-
istance of the strain responsible for the index case [52]. However,
nly a few of the second-line oral drugs are available in pediatric for-
ulations, and this could lead to dosing errors and the consequent
isks of ineﬃcacy or toxicity and lack of compliance. Furthermore,
ittle is known about the pediatric pharmacokinetics of this class of
rugs [52]. Although the latest-generation of ﬂuoroquinolones (e.g.
evoﬂoxacin and moxiﬂoxacin) have proved to be more eﬃcacious in
itro than their predecessor (oﬂoxacin) [52], their use in children has
een insuﬃciently studied [65,66], and the recent increase in their
se to treat non-tuberculous infections in adults has raised concerns
bout a potential increase in bacterial resistance. Consequently, the
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Table 4
Suggested chemoprophylactic drugs for children who have come into contact with a case of MDR-TB.
Drugs Characteristics Suggested dose Unwanted effects Comments
First-line oral antitubercular
drugs
Isoniazid Inhibits the synthesis of the cell
wall of mycobacteria by
inhibiting the synthesis of
mycolic acid; bacteriocidal;
rapidly absorbed; high tissue
distribution
Standard dose: 10 mg/kg once a
day (up to a maximum of
300 mg/day) High dose:
15–20 mg/kg once a day (up
to a maximum of 400 mg/day)
(Rare) Hypersensitivity;
gastrointestinal disorders;
peri-pheral neuro-pathy (due
to reduced pyri-doxine
levels); hepatitis. Well
tolerated even at high doses.
In the case of risk factors for
peri-pheral neuro-pathy (e.g.
mal-nutrition, HIV infection,
dia-betes), give pyridoxine
(10–50 mg/day). Better
absorbed if taken an empty
stomach.
Rifampicin Bactericidal; inhibits
DNA-dependent RNA
poiymerase; high tissue
distribution.
10–20 mg/kg once a day
(maximum 600 mg/day)
Hepatitis; reddish colour of
secretions.
High rate of resistance. Better
absorbed if taken an empty
stomach.
Ethambutol Bacteriostatic (bactericidal at
high doses); inhibits cell wall
synthesis; generally good
absorption and distribution,
but not in cerebro-spinal ﬂuid.
15–25 mg/kg once a day
(maximum 1.5 g/day)
Optical neuritis; peripheral
neuropathy; hypersensitivity;
gastrointestinal disorders.
Resistance rare (but diﬃcult to
evaluate). Eﬃcacious. Visual
ﬁeld and colour vision need to
be monitored. Not registered
for administration to children
aged < 5 years.
Pyrazinamide Bacteriostatic; well absorbed
and widely distributed; active
at low pH.
15–30 mg/kg once a day (up to a
maximum of 2 g/day).
Hepatitis; hyper-uricemia;
myal-gia; arthralgia; rash;
photo-sensitivity;
gastrointestinal disorders.
Adherence may be limited by
severe side effects des-cribed
in adults.
Unwanted effects may be
reduced if taken with food.
Rapid liver function
monitoring required. Stop any
hepatotoxic treatment if there
are signs of hepatitis.
Group 2: Fluoroquinolones
(oﬂoxacin, levoﬂoxacin,
moxiﬂoxacin) N.B. Not
registered for pediatric use
Bactericidal activity; inhibition
of DNA gyrase; well absorbed
and widely distributed.
Oﬂoxacin: 15–20 mg/kg once a
day (maxi–mum dose
900 mg/day). Levoﬂaxin:
10–25 mg/kg once a day
(maxi–mum 1000 mg/day).
Moxiﬂoxacin: 10 mg/kg once a
day (maxi–mum 400 mg/day)
Sleep disorders; arthralgia;
gastrointestinal disorders;
peri- pheral neuro-pathy;
headache; possible
photo-sensitivity
(levo-ﬂoxacin); long QT
syndrome.
To avoid excessively alkaline
urine, patients should be
advised to increase their ﬂuid
intake. The eﬃcacy of
levo-ﬂoxacin during the latent
phase may make it suitable
for prophylaxis.
Fluoroquinolones are the
drugs of choice in adults with
TB-MDR and TB-XDR.
Group 3: Injectable
antitubercular drugs
(aminoglycosides: amikacin,
kanamycin, streptomycin;
polypeptides: capreomycin,
viomycin) N.B. Not all
registered for pediatric use
Bactericidal action with high
degree of extra-cellular
activity; both categories
inhibit protein synthesis
Amikacin: 15–20 mg/kg twice a
day (maxi–mum 1000 mg per
dose). Kanamycin: 15 mg/kg.
Streptomycin:
20–40 mg/kg/day (adults
15 mg/kg/day), up to a
maximum dose of 1 g/day;
only intramuscular.
Capreomycin:
15–30 mg/kg/day (adults
1 g/day, do not exceed
20 mg/kg/day)
Nephrotoxicity; ototoxicity;
muscle pains; kypokalemia
Aminoglycosides do not cross
the blood/brain barrier.
Resistance to streptomycin is
very frequent and the
resistance evaluation test
unreliable. High risk of major
adverse events.
Group 4: second-line oral
antitubercular drugs:
thioamides (ethionamide and
protionamide); cycloserine
(and its terizidone derivative)
N.B. Not registered for
pediatric use
Ethionamide and protionamide:
bacteriostatic; well absorbed
and widely distributed;
inhibit cell wall synthesis by
inhibiting mycolic acid.
Cycloserine: bacteriostatic,
competitively inhibits the
enzymes involved in the
constitution of the cell walls
of mycobacteria.
Ethionamide and
protio-namide:
15–20 mg/kg/day in three
daily doses (maxi–mum
1 g/day).
Cycloserine:15 mg/kg/day in
three daily doses (maxi–mum
1 g/day)
Ethionamide and protionamide:
gastrointestinal disorders;
hepa-titis; metallic taste I the
mouth; hypothyroidism;
hypersensitivity;
hypoglycemia. Cycloserine:
psychotic reactions; visual
diﬃculties.
Ethionamide and protionamide:
it is essential to monitor liver
and thyroid function. In the
case of severe
gastro-intestinal disorders,
administer other treatments
separately while decreasing
the daily dose, or start with a
low dose and increase it over
time
Group 5: less eﬃcacious or less
widely studied drugs
(clofazimine, linezolid,
clarithromycin) N.B. Not all
registered for pediatric use
There are few data concerning
the use of this heterogeneous
group of drugs in the
treatment of TB.
Clofazimine: 50 mg on alternate
days in children aged < 10
years or 50–100 mg/day in
adolescents and adults.
Linezolid: 10 mg/kg three
times a day, up to a maximum
of 600 mg/day.
Clarithromycin: 15 mg/kg/day
in two doses, up to a
maxi–mum of 500 mg per
dose.
Clofazimine: photosensitivity;
gastrointestinal disorders.
Linezolid: dia-rrhea; nausea;
vomiting; ane-mia;
thrombo-cytopenia; opti-cal
and peri-pheral neuritis.
Clarithromycin: well
tolerated.
The pediatric safety and
eﬃ-cacy of clofazi-mine have
not been esta-blished;
further-more, it is not readily
available. The use of line-zolid
should be reserved for the
severe cases (e.g. resistant to
> 7 anti-tubercular drugs),
and hemochrome should be
monitored. Its poor eﬃcacy
means that the role of
clarithro-mycin is not clear.
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Table 5
Use of molecular typing in analysing epidemics.
Technique Discriminating power Time of execution
(strain)
Diﬃculty of
interpreting data
Execution using positive excreted/
aspirated gastric material
Spoligotyping Low 48 h Low Yes
24-loci MIRU-VNTR typing (current
gold standard)
High (mediium for Beijing lineage) 48 h Low No; a partial proﬁle can be obtained
from positive samples
IS6110-RFLP Typing High (low for strains with < 6 IS6110
copy numbers)
5–6 weeks Medium–high No
WGS High 5–6 days Medium–high No
WGS= whole-genome sequencing.
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pmerican Academy of Pediatrics recommends restricting the pedi-
tric use of ﬂuoroquinolones to selected cases for which there is no
afe and effective pharmacological alternative [65].
The administration of combinations of anti-tuberculous drugs
ay have some advantages: a standard regimen may not be uni-
ersally appropriate, but individualised regimens based on the
usceptibility proﬁle of the strain isolated in the index case could
ncrease the probability of eﬃcacy and reduce the probability of
esistance. However, the extensive testing necessary would require
similar effort to that of treating the disease itself and the costs per
atient (and for national health services) have not been evaluated.
urthermore, as clinical monitoring would be fundamental in order
o determine the response to either single-drug or combined pro-
hylaxis, identify adverse events promptly and promote compliance,
strict follow-up during the 24 months following contact, with
he rapid identiﬁcation and treatment of developing TB may be a
easonable alternative [34,49].
In conclusion, the use of primary chemoprophylaxis in children
xposed to MDR-TB remains a subject of debate. Its eﬃcacy has been
valuated in only a few studies, none of which was a randomised and
ontrolled clinical trial. Although some of the data seem to indicate
n advantage, particularly in speciﬁc subgroups of contacts at high
isk (the immunocompromised and children aged ≤5 years), there
s no agreement in the literature concerning the preferred regimen.
lose contacts are more likely to become infected and using the sus-
eptibility proﬁle of the strain isolated in the index case should be
onsidered when making decisions concerning chemoprophylaxis.
ow should molecular typing be used when analysing
pidemics?
In order to be able to adopt eﬃcient control measures, it is crucial
o understand the transmission mechanisms and pathways of the M.
uberculosis strains causing epidemics, but the analysis needs to be
ade as soon as isolates become available if it is to be an effective aid
o classic epidemiological studies [67]. As childhood pulmonary TB is
ypically paucibacillar and therefore not very infectious, it is generally
elieved that children rarely represent the index case of an epidemic,
hich is more likely to be one of their adult or adolescent contacts.
Molecular typing can be used to reconstruct the chains of
ransmission involving children when a clinical isolate is available
culture-positive cases) and so, in addition to abvious reasons of di-
gnosis, every effort should be made to obtain a cultured isolate.
The main molecular typing techniques are spoligotyping, IS6110-
FLP typing, MIRU-VNTR typing, and the analysis of punctiform
utations by means of new-generation whole-genome sequencing
WGS) [68,69]. Table 5 brieﬂy summarises the discriminatory power
nd execution/response times of each of these techniques. They cur-
ently almost always need to have a strain isolated in culture in order
o be able to obtain suﬃcient high-quality genomic material, but it is
ossible that future improvements in technology sequencing will al-
ow reliable and epidemiologicaly useful results to be obtained from
microscopically positive sample.A spoligotyping analysis can already be directly made using such a
ample provided it contains more than 104 mycobacteria/mL, but its
iscriminatory power is relatively low regardless of whether a cul-
ured sample or genomic material is used and, although it may be
seful when it is necessary to exclude the possibility that a sample
elongs to an epidemic cluster, this prevents it from being used to an
pidemiological link [68,70]. It cannot distinguish different strains of
he same family, and the clearly identiﬁable Beijing proﬁle is predom-
nant in many eastern European and south-eastern Asian countries.
The new gold standard for analysing epidemic foci (which has re-
laced IS6110-RFLP s 24-locus MIRU-VNTR typing, which has to be
arried out by reference centres validated by an external quality con-
rol agency. The technique may be automated or carried out manu-
lly but, in both cases, reference strains have to be included in order
o control the quality of the ﬁndings [69]. If the isolated strain be-
ongs to the Beijing family, its MIRU-VNTR proﬁle does not conﬁrm
hat it belongs to the epidemic cluster unless there is clear evidence
f contact: a second level of analysis is necessary that requires the
valuation of four hyper-variable loci in addition to the standard 24
71]. Strains with differentMIRU-VNTR proﬁles in two ormore loci do
ot belong to the same recent chain of transmission, but strains with
nly one different locus may belong to the same cluster, particularly
f the locus is hyper-variable [71,72].
The most recent literature shows that WGS typing techniques can
rovide a more reliable picture of transmission, especially in the case
f large longitudinal clusters. If there are no epidemiological data in-
icating that contact has taken place, it is necessary to use WGS and
ingle-nucleotide polymorphism (SNP) analysis to distinguish strains
ith identical MIRU-VNTR proﬁles. On the basis of the currently
vailable data, strains with more than three different SNPs are con-
idered not to belong the same cluster if the analysis is made using
n appropriately ﬁltered genome that excludes the hyper-variable re-
eat regions (PPE, PE_PGRS, ESX) responsible for increasing the num-
er of SNPs unrelated to time-dependent genomic variations. The
ather complex analysis of the data has to be made by a reference
entre because both the quality of the sequencing and its interpre-
ation may lead to misleading results by generating false clusters or
xcluding real transmissions [73]. It is possible thatWGSwill become
he gold standard for the molecular analysis of epidemics.
onclusions
On the basis of the published evidence and their own clinical ex-
erience, the group of experts reached the following conclusions:
(1) The following social, exposure and demographic factors must
e considered risk factors for tuberculous infection and disease, and
hould be carefully considered when clinically evaluating pediatric
atients with suspected TB:
Exposure factors
- Direct contact with TB patients [III-A], particularly those who are
expectorate/gastric aspirate positive and/or whose chest X-rays
show signs of cavitating TB [I-A];
- Immune impairment or cancerous diseases [V-B].
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- Socially disadvantaged conditions (e.g. over-crowding, homeless-
ness, inadequate domestic ventilation) [III-A];
- Low family income [III-A];
- Illiterate or poorly educated parents (particularly mothers) [III-
A];
- Coming from a country that is highly epidemic for TB [III-A].
The co-existence of two or more of the above factors signiﬁcantly
increases the risk of tubercular infection [III-A]. Their absence does
not imply that there is no need to suspect TB.
(2) Subjects with the following conditions are at increased risk of
developing TB:
- HIV infection [I-A];
- Congenital immunodeﬁciency, particularly that involving T cells
and the oxide reductase metabolism of phagocytes [VI-A];
- Prolonged systemic corticosteroid therapy [VI-A];
- Biological drug therapies [VI-A];
- Oncological diseases [I-A];
- Organ or tissue transplantation [VI-A];
- Malnutrition [VI-A].
(3) The contacts of cases of TB should be sought using the method
of concentric circles based on the duration of exposure and the vol-
ume of the shared environment, with priority given to the contacts
who have spent at least eight hourswith the index case in an enclosed
space or who are at greater risk of developing the disease [III-A]. The
available means of screening contacts for TB are a TST, an IGRA and a
chest X-ray [III-A]. The available evidence does not support using an
IGRA as an alternative to a TST [III-B].
Children aged ≤5 years who have been exposed to a case of pul-
monary TB should undergo a TST, an IGRA and chest radiography
in order to exclude tuberculous disease [III-A]. If the TST, IGRA and
chest X-ray are negative, primary chemoprophylaxis with isoniazid
10mg/kg/day should be given for 8–12 weeks (throughout the period
of incubation), and the TST and IGRA should be repeated; if they are
still negative, the chemoprophylaxis should be stopped [III-A]. How-
ever, if they have become positive, but the child is asymptomatic and
a chest X-ray is negative, he or she should be considered as having
LTBI and preventive chemotherapy should be continued (for a total
of 6–9 months if the child is immunocompetent or 12 months if the
child is immunocompromised) [III-A]. If the TST/IGRA become posi-
tive and the patient is symptomatic or the X-ray ﬁndings are abnor-
mal, the diagnosis of tuberculous disease is to be considered likely
[III-A].
Children aged >5 years who have been exposed to a case of pul-
monary TB should also be tested in order to exclude tuberculous in-
fection [III-A]. If the TST, IGRA and chest X-ray are negative, primary
chemoprophylaxis is not necessary unless the child is immunocom-
promised, in which case isoniazid treatment should be given for 8–12
weeks [III-A]. After this period, all exposed children should undergo
another TST and IGRA in order to exclude tuberculous infection [III-
]. If these are negative, no treatment should be started but, if the
tests are positive, a chest X-ray is required [III-A]. If the X-ray is neg-
ative and the child is asymptomatic, he or she should be diagnosed
as having LTBI and isoniazid treatment should be started [III-A]. If
the TST and IGRA are positive and the patient is symptomatic and/or
the X-ray ﬁndings are abnormal, tuberculous disease should be diag-
nosed and speciﬁc treatment started [III-A].
(4) A child with LTBI has a positive TST and/or IGRA, no clinical
signs of disease, and a chest X-ray that may be normal or show
evidence of remote infection [III-A]. The administration of isoniazid
at a dose of 10 mg/kg/day (maximum dose 300 mg/day) for at least
six months reduces the risk of pulmonary and extra-pulmonary
TB, and the mortality associated with them [I-A]. Short-term pre-
ventive chemotherapy with isoniazid 10 mg/kg/day (maximumose 300 mg/day) and rifampicin 10 mg/kg/day (maximum dose
00 mg/day) for 3–4 months seems to be as eﬃcacious as isoniazid
onotherapy and leads to greater compliance [VI-B]. Laboratory
onitoring is not recommended for children taking isoniazid alone,
ut is required in the case of the onset of signs or symptoms of possi-
le adverse events [I-A]. Pyridoxine (vitamin B6) should be given at a
ose of 10–25 mg/day to breastfeeding infants and children with di-
betes, HIV infection, malnutrition or peripheral neuropathy [III-B].
(5) Primary chemoprophylaxis in the general population of chil-
ren exposed to MDR-TB is not recommended because there are no
tudies that clearly show it is effective in preventing the progression
o active TB, there is a risk of drug-related adverse events, and there
s also a risk that the selection of strains with an even narrower spec-
rum of sensitivity will reduce possible future therapeutic options if
ctive disease develops [V-C]. In such cases, a reasonable approach is
o monitor the child closely for 24 months in order to identify and
reat developing TB promptly [V-B]. Primary chemoprophylaxis can
e considered for speciﬁc subgroups of children at high risk of devel-
ping a severe clinical picture, such as those who are immunocom-
romised or aged<5 years [V-B]; in these cases, the prophylactic reg-
men should be chosen on the basis of in vitro tests of the sensitivity
f the strain isolated in the index case [V-B].
(6) In order to be able to adopt eﬃcient control measures, it is
rucial to clarify the transmission mechanisms and pathways of the
. tuberculosis strains that cause epidemic foci and, to this end, an
liquot of every positive culture should be sent a reference centre
VI-B]. Molecular typing should always be used to conﬁrm or exclude
ransmission, and intensify control measures [VI-B].
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